Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/10/2023* -- Results Q4 2022 -- -0.53 --
11/03/2022 -- Results Q3 2022 -0.50 -0.49 -2.11%
08/04/2022 -- Results Q2 2022 -0.69 -0.70 1.81%
05/05/2022 -- Results Q1 2022 -0.69 -0.80 13.32%
02/10/2022 -- Results Q4 2021 -0.92 -0.71 -30.33%
11/05/2021 -- Results Q3 2021 -0.72 -0.53 -35.55%
08/06/2021 -- Results Q2 2021 -0.60 -0.43 -39.24%
05/06/2021 -- Results Q1 2021 -0.50 -0.38 -30.88%
*Estimated Date/Time

Earnings

Next Report Date 02/10/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/03/2022
Beat/Miss Upgrade
Return Since 5.76%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
URL https://www.allovir.com
Investor Relations URL https://ir.allovir.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style N/A
Next Earnings Release Feb. 10, 2023 (est.)
Last Earnings Release Nov. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio --
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
--
--
--
-66.34%
-43.28%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-14.29%
-36.32%
-81.84%
12.49%
51.87%
218.8%
27.43%
-39.11%
-57.46%
-67.80%
-28.59%
-49.84%
-47.69%
-93.17%
229.0%
-48.60%
-51.09%
-87.17%
63.37%
16.67%
-79.93%
-17.17%
8.91%
-45.97%
-82.70%
-44.57%
-56.37%
48.58%
-52.96%
5.47%
10.67%
-77.09%
43.68%
As of November 25, 2022.

Profile

Edit
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
URL https://www.allovir.com
Investor Relations URL https://ir.allovir.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style N/A
Next Earnings Release Feb. 10, 2023 (est.)
Last Earnings Release Nov. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter ALVR Tweets